Future therapies for inflammatory bowel disease.
Three domains are accepted components of the etiology of inflammatory bowel disease (IBD): genetic predisposition, environmental stimuli, and abnormal immune response. The latter two are reasonable targets for medical therapies in the near future, whereas all three merit consideration for the more distant future as techniques of genetic manipulation evolve. In this review we summarize some of the fundamental concepts and offer comments on treatments for IBD that are likely and desirable in the near and distant future.
University of Virginia Digestive Health Center of Excellence (UVA-DHCOE), MSB-2nd floor, Room 2121, Charlottesville, VA 22908-0708, USA. FC4Q@hscmail.mcc.virginia.edu
Stephen J
SJ
Bickston
Lawrence W
LW
Comerford
Fabio
F
Cominelli
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016503:Drug Delivery Systems; D020022:Genetic Predisposition to Disease; D015316:Genetic Therapy; D015395:Histocompatibility Antigens Class I; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D000069285:Infliximab; D007778:Lactobacillus; D023421:Models, Animal; D010455:Peptides / Q000627:therapeutic use; D019936:Probiotics / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha
D000911:Antibodies, Monoclonal; D015395:Histocompatibility Antigens Class I; D010455:Peptides; D014409:Tumor Necrosis Factor-alpha; C092373:allotrap; D000069285:Infliximab